Adoptive cellular immunotherapy for viral diseases (Q36992981)

17 August 2017

1 reference

title

Adoptive cellular immunotherapy for viral diseases (English)

1 reference

17 August 2017

1 reference

2

Rooney CM

1 reference

17 August 2017

3

Heslop HE

1 reference

17 August 2017

Fujita Y

1

1 reference

PubMed ID

17982497

17 August 2017

language of work or name

English

0 references

publication date

5 November 2007

1 reference

Bone Marrow Transplantation

17 August 2017

1 reference

17 August 2017

41

1 reference

17 August 2017

2

1 reference

17 August 2017

193-198

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705906

17 August 2017

0 references

cites work

Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Epstein-Barr virus: 40 years on

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Preemptive Therapy of EBV-Related Lymphoproliferative Disease after Pediatric Haploidentical Stem Cell Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Post-transplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

An inducible caspase 9 safety switch for T-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Malignant effusions and immunogenic tumour-derived exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Antitumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

7 January 2021

Donor T cells to treat EBV-associated lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

7 January 2021

Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

7 January 2021

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705906

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705906

1 reference

PubMed ID

17982497

Dimensions Publication ID

17 August 2017

0 references

1 reference

PubMed ID

17982497